醫藥品·生物科技交易的權利金費率(2010年～2025年)

"製藥和生物技術交易中的特許權使用費率" 報告為您提供數千筆交易的真實信息，包括許可技術、特許權使用費率、許可費、預付款和里程碑付款。

本報告詳細介紹了製藥、生物技術和診斷領域最新公佈的合作項目，並揭露了特許權使用費率。本報告涵蓋了2010年至2025年間超過1,700個合作項目，並揭露了特許權使用費率。

本報告概述了公司如何以及為何簽訂在化合物或技術商業化後支付特許權使用費的合作協議。

了解潛在合作夥伴協商的交易條款的彈性，可以為談判過程提供重要的參考，從而了解談判期間的預期結果。雖然許多中小企業會尋求詳細的付款條款，但在付款方式方面，細節決定成敗。

本報告全面列出了自2010年以來宣布的1,700多筆合作交易，這些交易披露了 "當前協議" 交易和合作資料庫中記錄的量化特許權使用費率。每筆交易記錄和特許權使用費率揭露都透過交易線上副本的連結進行詳細說明，其中包括公司及其合作夥伴向美國證券交易委員會提交的實際合約文件（如有）。

本報告的第一章探討了自2010年以來製藥和生物技術領域的特許權使用費率趨勢。第一章對報告進行了介紹，第二章概述了自2010年以來製藥和生物技術領域的特許權使用費率趨勢。

第三章更深入地探討了特許權使用費率條款的結構以及它們如何與合作協議的其他財務條款相協調。

第四章深入分析了主動揭露特許權使用費率的公司以及特許權使用費率最高的交易。

第五章全面詳細地介紹了自2010年以來披露特許權使用費率的交易，並提供合約文件。合約文件詳細介紹了雙方就特許權使用費率達成的實際條款和條件。

報告還提供了一個全面的交易目錄，列出了自2010年以來所有揭露特許權使用費率的交易。交易按公司名稱、簽約時的開發階段、治療領域和技術類型進行分類。每個交易標題都提供了一個指向交易記錄線上版本的超鏈接，其中包括實際的合約文件。

報告還包含大量圖表，展示了自2010年以來製藥和生物技術交易中特許權使用費率的趨勢。

總之，本報告為交易撮合者提供了他們需要了解的有關製藥和生物技術領域特許權使用費率的所有資訊。

主要優勢

製藥和生技專利費率有以下優點：

• 了解自2010年以來的專利費率趨勢
• 透過實際案例研究分析專利費率條款結構
• 取得揭露專利費率的合作和授權協議
• 基準分析 - 確定交易市場價值
• 財務條款 - 首付款、里程碑付款、專利費
• 依公司A-Z、治療重點及技術類型分類的交易目錄
• 取得合約文件 - 深入了解交易結構
• 盡職調查 - 評估擬議交易條款對合作夥伴公司的適用性
• 節省數百小時的研究時間

範圍

• 本報告旨在詳細了解世界領先生命科學公司達成的交易的專利費率趨勢和結構。

製藥和生技交易中的特許權使用費率包括：

• 2010 年以來生物製藥業的特許權使用費率趨勢
• 特許權使用費率條款的結構分析
• 包含特許權使用費率揭露的實際授權協議案例研究
• 2010 年以來包含特許權使用費率揭露的許可協議綜合列表
• 存取包含特許權使用費率揭露的授權協議文件
• 2010 年以來按特許權使用費率金額劃分的主要許可協議
• 2010 年以來最活躍的特許權使用費率揭露

製藥和生物技術交易中的特許權使用費率列出了可用的交易和協議。

• 公司 A-Z
• 標題金額
• 治療領域
• 技術類型
• 每個交易標題都透過網頁連結連結到實際交易記錄的線上版本。
• "製藥和生物技術特許權使用費率報告" 提供對許可協議現有合約文件的全面存取。

分析實際協議可以讓您評估：

• 授予的具體特許權使用費率是多少？
• 每個合作公司實際獲得的授權是多少？
• 授予了哪些獨家權利？
• 協議的付款結構是怎樣的？
• 如何審計銷售和付款？
• 合約期限是怎樣的？
• 協議的關鍵條款是如何定義的？
• 智慧財產權的處理和所有權是什麼？
• 誰負責商業化？
• 誰負責開發、供應和製造？
• 如何管理保密權和揭露權？
• 如何處理糾紛？如何解決？
• 合約在什麼情況下可以終止？
• 如果所有權改變會發生什麼事？
• 雙方約定了哪些再授權或分包條款？
• 公司堅持哪些標準條款？
• 哪些標準條款似乎因合作夥伴或交易類型而異？
• 公司主張哪一契約法管轄權？

目錄

摘要整理

第1章 簡介

• 什麼是特許權使用費？
• 特許權使用費率歷史
• 製藥和生物技術領域的特許權使用費率
• 特許權使用費率與收益分成
• 報告概述

第二章：製藥和生物技術特許權使用費率概述

• 2010 年至 2025 年特許權使用費率趨勢
• 收益分成計算方法
• 近期文獻綜述
• 未來特許權使用費率

第三章：製藥和生技交易中的特許權使用費率條款

• 合作協議結構
• 典型的特許權使用費率條款結構
• 特許權使用費率條款範例

第四章：主動揭露特許權使用費率的公司

• 最主動揭露特許權使用費率的公司費率

第5章 特許權比率契約名錄

• 找出交易協議中的特許費率，深入了解
• 交易目錄
• 交易目錄 - 交易特許費率 - 按公司 (AZ)
• 交易目錄 - 交易特許費率 - 按治療領域
• 交易目錄 - 交易特許費率 - 按協議簽訂時的開發階段
• 交易目錄 - 交易特許費率 - 按技術類型
• 特許費率參考
• 特許費率協議範例
• 關於研究公司
• 當前合作夥伴關係
• 當前協議
• 目前合作夥伴的最新報告標題

Royalty Rates in Pharmaceutical and Biotechnology Deals is your one-stop source for providing real-deal information on thousands of transactions, including the technology licensed, royalty rates, license fees, upfront and milestone payments.

This report provides details of the latest partnering deals which disclose a royalty rate announced in the pharmaceutical, biotechnology and diagnostic sectors. The report provides details of 1,700+ partnering deals disclosing royalty rates from 2010 to 2025.

The report provides an overview of how and why companies enter partnering deals where a royalty is payable upon commercialization of the compound or technology.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of 1,700+ partnering deals announced since 2010 where a quantitative royalty rate has been disclosed, as recorded in the Current Agreements deals and alliances database. Each deal record and royalty disclosure is available in further detail via a link to online copy of the deal including actual contract document, where available, as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of royalty rate trends in pharma and biotech since 2010. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in royalty rates in the pharma and biotech sectors since 2010.

Chapter 3 provides a more detailed insight into the structure of a royalty rate clause and how it fits with the other financial terms of the partnering deal.

Chapter 4 provides an insight into companies active in disclosing royalty rates as well as those deals attracting the highest royalty rates.

Chapter 5 provides comprehensive and detailed access to deals which disclose a royalty rate since 2010 where a contract document is available. Contract documents provide an in-depth insight into the actual deal terms agreed between the parties with respect to the royalty rate.

In addition the report includes a comprehensive deal directory listing of all deals where a royalty rate has been disclosed announced since 2010. Each listing is organized as a directory by company A-Z, stage of development at signing, therapeutic area, and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends in royalty rates in pharma and biotech deal making since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about royalty rates in the pharma and biotech sector.

Key benefits

Royalty Rates in Pharmaceutical and Biotechnology Deals provides the following benefits:

• Understand royalty rate trends since 2010
• Analysis of the structure of royalty clauses with real life case studies
• Browse collaboration and licensing deals which reveal a royalty rate
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Royalty Rates in Pharmaceutical and Biotechnology Deals is intended to provide the reader with an in-depth understanding of the royalty rate trends and structure of deals entered into by leading life science companies worldwide.

Royalty Rates in Pharmaceutical and Biotechnology Deals includes:

• Trends in royalty rates in the biopharma industry since 2010
• Analysis of royalty rate clause structure
• Case studies of real-life licensing deals which disclose royalty rates
• Comprehensive listing of licensing deals which disclose royalty rates since 2010
• Access to licensing contract documents which disclose royalty rates
• The leading licensing deals by royalty rate value since 2010
• Most active royalty rate disclosures since 2010

In Royalty Rates in Pharmaceutical and Biotechnology Deals available deals and contracts are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.
• The Royalty Rates in Pharmaceutical and Biotechnology Deals report provides comprehensive access to available contract documents for licensing deals.

Analyzing actual contract agreements allows assessment of the following:

• What are the precise royalty rates granted?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

• 1.1. What are royalties?
• 1.2. History of royalty rates
• 1.3. Royalties in pharmaceuticals and biotechnology
• 1.4. Royalties versus revenue share
• 1.5. Overview of the report

Chapter 2 - An overview of pharmaceutical and biotechnology royalty rates

• 2.1. Trends in royalty rates 2010 - 2025
• 2.2. How do revenue shares figure?
• 2.3. A review of recent literature
• 2.4. Royalty rates in the future

Chapter 3 - The royalty clause in pharmaceutical and biotechnology deals

• 3.1. Partnering agreement structure
• 3.2. Structure of a typical royalty clause
• 3.3. Example royalty clauses
  • 3.3.1. Case study 1
  • 3.3.2. Case study 2
  • 3.3.3. Case study 3
  • 3.3.4. Case study 4

Chapter 4 - Companies actively disclosing royalty rates

• 4.1. Most active companies in disclosing royalty rates

Chapter 5 - Royalty rate contract directory

• Explore royalty rates within the deal contract document to gain greater insight
• Deal Directory
• Deal Directory - Royalty rates in deals - by company A-Z
• Deal Directory - Royalty rates in deals - by therapy area
• Deal Directory - Royalty rates in deals - by stage of development at signing
• Deal Directory - Royalty rates in deals - by technology type
• Royalty rate references
• Example royalty rate deal contract document
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Trends in pharma and biotech royalty rates, 2010 - 2025
• Figure 2: Components of the partnering deal structure
• Figure 3: Components of the partnering royalty clause
• Figure 4: Most active companies disclosing royalty rate 2010 - 2025
• Figure 5: Licensing agreement for rhAAT - rEVO Biologics, LFB Biotechnologies